NovaBridge Biosciences Total Liabilities
NovaBridge Biosciences total liabilities. Based on the latest financial reports, NovaBridge Biosciences (NBP) has total liabilities worth $30.44 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check NovaBridge Biosciences (NBP) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of NovaBridge Biosciences (2017–2025)
Total liabilities of NovaBridge Biosciences from 2017 to 2025. This chart illustrates how NovaBridge Biosciences's total liabilities have evolved over time, based on quarterly financial data. Explore NovaBridge Biosciences (NBP) investment intensity to see how much of total assets are deployed in long-term investments.
NovaBridge Biosciences Competitors by Total Liabilities
The table below lists competitors of NovaBridge Biosciences ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Teo Seng Capital Bhd
KLSE:7252
|
Malaysia | RM265.96 Million |
|
Bharat Wire Ropes Limited
NSE:BHARATWIRE
|
India | Rs1.79 Billion |
|
O-TA Precision Industry Co Ltd
TWO:8924
|
Taiwan | NT$1.85 Billion |
|
Excel Industries Limited
NSE:EXCELINDUS
|
India | Rs4.02 Billion |
|
STLLR Gold Inc.
TO:STLR
|
Canada | CA$8.05 Million |
|
Western Forest Products Inc
TO:WEF
|
Canada | CA$262.00 Million |
|
Gold Resource Corporation
NYSE MKT:GORO
|
USA | $138.38 Million |
|
Airtel Africa Plc
LSE:AAF
|
UK | GBX10.23 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down NovaBridge Biosciences's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see NovaBridge Biosciences balance sheet assets.
Liquidity & Leverage Metrics
NovaBridge Biosciences Total Liabilities Ratios Explained
NovaBridge Biosciences total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.64 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NovaBridge Biosciences's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NovaBridge Biosciences (2017–2025)
The table below shows the annual total liabilities of NovaBridge Biosciences from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.23 Million | -94.97% |
| 2024-12-31 | $84.08 Million | -33.45% |
| 2023-12-31 | $126.34 Million | -88.14% |
| 2022-12-31 | $1.07 Billion | +551.92% |
| 2021-12-31 | $163.42 Million | -77.05% |
| 2020-12-31 | $712.19 Million | -81.12% |
| 2019-12-31 | $3.77 Billion | +13.25% |
| 2018-12-31 | $3.33 Billion | +151.37% |
| 2017-12-31 | $1.33 Billion | -- |
About NovaBridge Biosciences
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy… Read more